Detalhe da pesquisa
1.
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Int J Cancer
; 149(7): 1463-1472, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34109630
2.
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Clin Transl Oncol
; 26(7): 1647-1663, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38530556
3.
Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.
J Med Case Rep
; 16(1): 365, 2022 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195892
4.
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Mol Oncol
; 15(9): 2363-2376, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34058070
5.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Eur J Cancer
; 108: 120-128, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30654297
6.
Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting.
Adv Ther
; 34(1): 136-147, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27873236
7.
SEOM clinical guidelines for the treatment of small-cell lung cancer.
Clin Transl Oncol
; 12(1): 27-31, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20080468